2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - La Nouvelle C
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

423 ENTRUST-IFM/PETHEMA: Preliminary results of the phase 2 portion of a phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of Etentamig and daratumumab in frail transplant-ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)

Salomon Manier, MD, PhD, Thierry Facon2, Jesus San-Miguel Sr, Md, PhD3, Malin Hultcrantz, MD PhD4, Xavier Leleu Sr, MD, PhD5, Hans C Lee, MD6, Shaji Kumar, MD7, Saurabh Chhabra, MD, MBBS8, Cyrille Touzeau Sr, MD, PhD9, Laura Rosiñol Dachs Sr, MD, PhD10, Alexia Suarez Cabrera, MD11, Peter Forsberg, MD12, Junya Kuroda, MD, PhD13, Tomoaki Fujisaki14, Kaustav Chatterjee, MD15, Anders Svensson, MD16, Mark Rocco, PhD17, Jovian Yu, MD, MS, MBA18, Emma L. Arriola, PhD19, Saketh Gudipati20, Myles Dillon, PhD21, Jennifer Lin, MS, MA22, Fan Wang23, Maria-Victoria Mateos Jr, MD, PhD24
1 Department of Hematology, Centre Hospitalier Universitaire Lille, Lille University, Lille, France
2 Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille, Lille, France
3 Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA) Universidad de Navarra Pamplona, Pamplona, Spain
4 Department of Medicine, Weill Cornell Medical College; Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Service d’Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France
6 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
8 Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, United States
9 Department of Hematology, University Hospital of Lille, Lille, France
10 Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Spain
11 Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain
12 University of Colorado Cancer Center, Comprehensive Cancer Center, Aurora, Colorado, United States
13 Division of Hematology and Oncology Department of Medicine Kyoto Prefectural University of Medicine, Kyoto, Japan
14 Department of Hematology, Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan
15 AbbVie Inc., North Chicago, Illinois, United States
16 AbbVie Inc., North Chicago, Illinois, United States
17 AbbVie Inc., South San Francisco, California, United States
18 AbbVie Inc., North Chicago, Illinois, United States
19 AbbVie Inc., North Chicago, Illinois, United States
20 AbbVie Inc., North Chicago, Illinois, United States
21 AbbVie Inc., North Chicago, Illinois, United States
22 AbbVie Inc., North Chicago, Illinois, United States
23 AbbVie Inc., North Chicago, Illinois, United States
24 Hospital Universitario de Salamanca/IBSAL/CIC/Ciberonc, Salamanca, Spain

Introduction: For patients with NDMM, treatment selection is primarily guided by transplant eligibility based on overall fitness. In TI patients, anti-CD38 monoclonal antibody-based combinations with bortezomib, lenalidomide, and dexamethasone (VRd) are considered standard of care (SoC). For frail patients, unsuitable for these therapies, daratumumab (D) with Rd is the current SoC.  Nevertheless, outcomes remain suboptimal for these patients, highlighting an unmet need for more effective strategies. T-cell–redirecting therapies that may provide deep and durable responses without the need for continuous treatment could be an attractive alternative. Etentamig is being developed as a next-generation differentiated B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, optimized for convenient monthly (Q4W) dosing from the start, and composed of a bivalent BCMA-binding domain with high avidity and a low-affinity CD3-binding domain potentially reducing cytokine release syndrome (CRS) and infection rates. Etentamig plus Dd has been shown to be safe and efficacious in patients with relapsed/refractory MM, with low rates of CRS (27%) and promising overall response rates (ORR: 70%), as reported in a preliminary analysis of the phase 1b Kilimanjaro trial (NCT05259839). Combination etentamig+D may provide an opportunity to improve SoC for frail, TI patients with NDMM.

Methods: This global, phase 2/3 multicenter, randomized, open-label, IFM/PETHEMA collaborative study (NCT07095452) evaluates the efficacy and safety of etentamig+D compared with DRd in frail, TI patients with NDMM. Key eligibility criteria include: ≥18 years of age, confirmed diagnosis of NDMM (per International Myeloma Working Group [IMWG] criteria), ineligible for autologous stem cell transplant and high-dose chemotherapy based on investigator judgment, and IMWG myeloma frailty score ≥1 (intermediate-frail to frail). In phase 2, patients were randomized 5:5:2 to receive 1 of 3 doses of intravenous etentamig Q4W in combination with 1800 mg of subcutaneous D (weekly [Cycles 1–2], Day 1 and Day 15 [Cycles 3–6], and Q4W [Cycle 7+]). The primary endpoint is clinical activity per IMWG 2016 response criteria, including ORR and rate of very good partial response or better (≥VGPR). Secondary endpoints include safety and tolerability, additional efficacy, pharmacokinetics, and immunogenicity. Data from phase 2 will inform the optimal recommended phase 3 dose (RP3D) of etentamig+D. In phase 3, patients will be randomized 1:1 to etentamig+D at the RP3D or DRd, administered per local label.

Results: As of 1 June 2026, 36 patients were enrolled in phase 2; with median (mdn) follow-up of 0.8 (0–4) months, all patients remain on treatment; 18 (50%) patients were treated in the outpatient setting. Across dose cohorts, 20 (56%) patients were male, 17 (74%) were White, and mdn age (range) was 79 (67–86) years. Mdn time from diagnosis was 1.0 month. Overall, 15 (42%) patients had an IMWG frailty index score of ≥2; most (25 [69%]) had International Staging System at diagnosis of I/II; MM subtype was immunoglobulin (Ig)G in 15 (42%), IgA in 12 (33%), and light-chain only in 8 (22%) patients. At baseline, 3 (8%) patients had soft tissue plasmacytomas.

With a short follow-up time at data cutoff, out of the efficacy evaluable patients, ORR was 92%, with 31% achieving ≥VGPR. Overall, the most frequent treatment-emergent adverse events (AEs) were neutropenia (9 [25%]), lymphopenia (8 [22%]), and fatigue (6 [17%]); most frequent grade (G) 3/4 AEs were lymphopenia (7 [19%]) and neutropenia (6 [17%]). Serious AEs occurred in 2 (6%) patients. CRS was infrequent, occurring in 5 (14%) patients (all G1); no immune effector cell-mediated neurotoxicity syndrome (ICANS) was reported; 13 (36%) patients received tocilizumab prophylaxis. No patients reported infusion-related reactions (IRR). Infections were reported in 2 (6%) patients with 1 G3 event (endocarditis); 10 (28%) patients received intravenous immunoglobulin.

Conclusions: These initial data support the promising efficacy and manageable safety profile of etentamig+D in this frail population, with low CRS and infection rates, with no ICANS and IRRs. Updated phase 2 data with approximately 60 patients will be presented at the meeting. Based on these findings, phase 3 will be initiated shortly.

Salomon Manier, MD, PhD: Pfizer - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Adaptive Biotechnology - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)